Literature DB >> 17106920

Colorectal cancer screening.

Ramona-M McLoughlin, Colm-A O'Morain.   

Abstract

Colorectal cancer is a major public health burden worldwide. There is clear-cut evidence that screening will reduce colorectal cancer mortality and the only contentious issue is which screening tool to use. Most evidence points towards screening with fecal occult blood testing. The immunochemical fecal occult blood tests have a higher sensitivity than the guaiac-based tests. In addition, their automation and haemoglobin quantification allows a threshold for colonoscopy to be selected that can be accommodated within individual health care systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17106920      PMCID: PMC4087426          DOI: 10.3748/wjg.v12.i42.6747

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  51 in total

Review 1.  Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy.

Authors:  James D Lewis; Kimmie Ng; Kenneth E Hung; Warren B Bilker; Jesse A Berlin; Colleen Brensinger; Anil K Rustgi
Journal:  Arch Intern Med       Date:  2003-02-24

2.  Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults.

Authors:  Perry J Pickhardt; J Richard Choi; Inku Hwang; James A Butler; Michael L Puckett; Hans A Hildebrandt; Roy K Wong; Pamela A Nugent; Pauline A Mysliwiec; William R Schindler
Journal:  N Engl J Med       Date:  2003-12-01       Impact factor: 91.245

3.  Methods and Economic Considerations: Group 1 Report. ESGE/UEGF Colorectal Cancer--Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20 - 22, 2003. fulfillment corporate.

Authors:  R J Steele; R Gnauck; R Hrcka; O Kronborg; C Kuntz; P Moayyedi; C O'Morain; J Spicák; H Vainio
Journal:  Endoscopy       Date:  2004-04       Impact factor: 10.093

4.  Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.

Authors:  Alex Vilkin; Paul Rozen; Zohar Levi; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Yaron Niv
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

5.  Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.

Authors:  Graeme P Young; D James B St John; Sidney J Winawer; Paul Rozen
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

6.  Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia.

Authors:  Peter B Cotton; Valerie L Durkalski; Benoit C Pineau; Yuko Y Palesch; Patrick D Mauldin; Brenda Hoffman; David J Vining; William C Small; John Affronti; Douglas Rex; Kenyon K Kopecky; Susan Ackerman; J Steven Burdick; Cecelia Brewington; Mary A Turner; Alvin Zfass; Andrew R Wright; Revathy B Iyer; Patrick Lynch; Michael V Sivak; Harold Butler
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

7.  Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population.

Authors:  Wai Man Wong; Shiu Kum Lam; Kwan Lok Cheung; Teresa Sze Man Tong; Paul Rozen; Graeme P Young; Kin Wah Chu; Judy Ho; Wai Lun Law; Hiu Ming Tung; Hok Kwok Choi; Yee Man Lee; Kam Chuen Lai; Wayne H C Hu; Chi Kuen Chan; Man Fung Yuen; Benjamin Chun-Yu Wong
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

8.  Prevalence of advanced neoplasia at screening colonoscopy in men in private practice versus academic and Veterans Affairs medical centers.

Authors:  Gavin C Harewood; David A Lieberman
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

9.  Cluster randomization trial of sequence mass screening for colorectal cancer.

Authors:  Shu Zheng; Kun Chen; Xiyong Liu; Xinyuan Ma; Hai Yu; Kang Chen; Kaiyan Yao; Lun Zhou; Linbo Wang; Peiling Qiu; Yongchuan Deng; Suzhan Zhang
Journal:  Dis Colon Rectum       Date:  2003-01       Impact factor: 4.585

10.  Community-based screening by colonoscopy or computed tomographic colonography in asymptomatic average-risk subjects.

Authors:  Rosie G Scott; John T Edwards; Lin Fritschi; Noellene M Foster; Richard M Mendelson; Geoffrey M Forbes
Journal:  Am J Gastroenterol       Date:  2004-06       Impact factor: 10.864

View more
  8 in total

1.  Factors influencing quality of bowel preparation for colonoscopy.

Authors:  Ronald V Romero; Sanjiv Mahadeva
Journal:  World J Gastrointest Endosc       Date:  2013-02-16

2.  Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening.

Authors:  Dao-Rong Wang; Dong Tang
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

3.  Use of colon cancer testing in rural Colorado primary care practices.

Authors:  Linda Overholser; Linda Zittleman; Allison Kempe; Caroline Bublitz Emsermann; Desiree B Froshaug; Deborah S Main; Rodrigo Araya-Guerra; Maret Felzien; John M Westfall
Journal:  J Gen Intern Med       Date:  2009-08-27       Impact factor: 5.128

4.  Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases.

Authors:  Ichiro Hirata; Masahiro Hoshimoto; Osamu Saito; Masanobu Kayazawa; Takashi Nishikawa; Mitsuyuki Murano; Ken Toshina; Fang-Yu Wang; Ryoichi Matsuse
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

5.  The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings.

Authors:  Salah H Elsafi; Norah I Alqahtani; Nawaf Y Zakary; Eidan M Al Zahrani
Journal:  Clin Exp Gastroenterol       Date:  2015-09-09

6.  FICE in Predicting Colorectal Flat Lesion Histology.

Authors:  Cevher Akarsu; Nuri A Sahbaz; Ahmet C Dural; Osman Kones; Sinan Binboga; Hamit A Kabuli; Alpen Y Gumusoglu; Halil Alis
Journal:  JSLS       Date:  2017 Oct-Dec       Impact factor: 2.172

7.  Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review.

Authors:  Sander Bach; Nina R Sluiter; Jamie J Beagan; Joost M Mekke; Johannes C F Ket; Nicole C T van Grieken; Renske D M Steenbergen; Bauke Ylstra; Geert Kazemier; Jurriaan B Tuynman
Journal:  JNCI Cancer Spectr       Date:  2019-06-19

8.  Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer.

Authors:  S Zanutto; S Pizzamiglio; M Ghilotti; C Bertan; F Ravagnani; F Perrone; E Leo; S Pilotti; P Verderio; M Gariboldi; M A Pierotti
Journal:  Br J Cancer       Date:  2014-01-14       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.